Brazil grants permission for clinical trial of new Chinese vaccine

2021-04-23 08:26:51Xinhua Editor : Li Yan ECNS App Download
Special: Battle Against Novel Coronavirus

Brazil's National Health Surveillance Agency (Anvisa) has authorized clinical trials of a new COVID-19 vaccine developed by China's Sichuan Clover Biopharmaceuticals, according to official statement, Reuters reported on Monday.

Anvisa said the company was authorized to conduct Phase II and III trials in Brazil, and Sichuan Clover is planning to test the vaccine on 22,000 volunteers in Latin America, South Africa, Belgium, China, Spain, Poland and the United Kingdom, said the report.

On the same day, CNBC reported that China's CanSino Biologics will be starting clinical trials next week for a COVID-19 vaccine that is administered through inhalation.

An inhaled vaccine could theoretically provide additional protection by activating antibodies in the airways, the company's co-founder and Chief Executive Xuefeng Yu told CNBC.


Most popular in 24h

MoreTop news


Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2021 All rights reserved.
Reproduction in whole or in part without permission is prohibited.